TY - JOUR
T1 - Combining radiotherapy with immunoscheckpoint inhibitors or CAR-T in renal cell carcinoma
AU - Santoni, Matteo
AU - Heng, Daniel Y.C.
AU - Aurilio, Gaetano
AU - Iozzelli, Andrea
AU - Servi, Lucilla
AU - Fabiani, Andrea
AU - Giannini, Massimo
AU - Mazzucchelli, Roberta
AU - Cimadamore, Alessia
AU - Scarpelli, Marina
AU - Zaghloul, Mohamed S.
AU - Battelli, Nicola
AU - Montironi, Rodolfo
N1 - Publisher Copyright:
© 2020 Bentham Science Publishers.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020
Y1 - 2020
N2 - Radiotherapy is considered a second life in Renal Cell Carcinoma (RCC) patients, mainly due to the introduction of immune checkpoint inhibitors, such as anti-Programmed-death (PD)-1, alone or in combination with anti-Cytotoxic T-Lymphocyte Antigen (CTLA)-4. Several trials are investigating the efficacy/safety of immune checkpoint inhibitors in sequential or combined strategies with radiotherapy. Chimeric Antigen Receptor (CAR)-T cells therapy as a promising approach in cancer patients has opened the way to novel possibilities of integrating therapies. The identification of biomarkers of tumor response to these combinations represents a challenge in RCC, together with the research for the best partner for immunotherapy in metastatic patients. In this review we illustrated preclinical/clinical data on the integration of radiotherapy with immunocheckpoint inhibitors or CART cells in RCC.
AB - Radiotherapy is considered a second life in Renal Cell Carcinoma (RCC) patients, mainly due to the introduction of immune checkpoint inhibitors, such as anti-Programmed-death (PD)-1, alone or in combination with anti-Cytotoxic T-Lymphocyte Antigen (CTLA)-4. Several trials are investigating the efficacy/safety of immune checkpoint inhibitors in sequential or combined strategies with radiotherapy. Chimeric Antigen Receptor (CAR)-T cells therapy as a promising approach in cancer patients has opened the way to novel possibilities of integrating therapies. The identification of biomarkers of tumor response to these combinations represents a challenge in RCC, together with the research for the best partner for immunotherapy in metastatic patients. In this review we illustrated preclinical/clinical data on the integration of radiotherapy with immunocheckpoint inhibitors or CART cells in RCC.
KW - CAR-T cells
KW - Immunocheckpoint inhibitors
KW - Immunotherapy
KW - Programmed-death-1
KW - Radiation therapy
KW - Renal cell carcinoma
UR - http://www.scopus.com/inward/record.url?scp=85081259085&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85081259085&partnerID=8YFLogxK
U2 - 10.2174/1389450120666191017113051
DO - 10.2174/1389450120666191017113051
M3 - Article
C2 - 31625471
AN - SCOPUS:85081259085
VL - 21
SP - 416
EP - 423
JO - Current Drug Targets
JF - Current Drug Targets
SN - 1389-4501
IS - 4
ER -